Home PDCI

07

Jul2020

NEW PDCI INFOGRAPHIC: Best Practices for CADTH Request for Reconsideration

PDCI Market Access Inc. is pleased to share its best practices infographic focused on Requesting Reconsideration under the Canadian Agency for Drugs and Technologies in Health (CADTH) Procedures for the Common Drug Review (CDR). While optional and only appropriate in select circumstances, manufacturers should not overlook this potential opportunity ... Read More

20

Jun2020

New Draft PMPRB Guidelines: A High Level Summary

As PDCI announced earlier today, the PMPRB has issued the second draft of the PMPRB Guidelines to support the implementation of Patented Medicines Regulations (Regulations) changes coming unto force on January 1, 2021.  This draft is now available for a 30-day Notice and Comment Period.  Written feedback ... Read More

01

Jun2020

PMPRB Guidelines and Regulations Update

PMPRB Guidelines and Regulations Update As first disclosed by PDCI last week, the PMPRB Board Chair officially confirmed that the amended Patented Medicines Regulations (“Regulations”) will now come into force on January 1, 2021.  These Regulations were published in Canada Gazette II in August 2019 with ... Read More

05

May2020

TargetPharma – CADTH Pharmaceutical Review Update 15

REMINDER: As announced last month, PDCI and its research partners are studying the private payer product listing agreement (PLA) landscape in Canada by surveying pharmaceutical manufacturers and private payers about their ... Read More

16

Apr2020

PDCI Launches 2020 Private Payer PLA Study

PDCI Market Access Inc. (PDCI), in collaboration with Connex Health Consulting, is excited to announce the launch of its 2020 Private Payer Product Listing Agreement (PLA) study! The objective of this research is to share insights about the private payer PLA landscape among pharmaceutical stakeholders ... Read More

06

Apr2020

PDCI Market Access Inc. Welcomes Mark Fleming as a Strategic Advisor

PDCI Market Access Inc. (PDCI), Canada’s leading pricing, reimbursement and health economics consultancy, is pleased to announce its strategic partnership with Mark Fleming.  Mark is joining PDCI as Strategic Advisor supporting PDCI’s pricing, market access and policy research activities.   ... Read More

31

Mar2020

PDCI Acquires Exclusive License for TELUS Health’s Market Access Toolkit Including INSIGHTS Magazine and Census of Insurers

We are excited to announce that PDCI Market Access Inc. (“PDCI”) has entered into an Exclusive License Agreement for the rights to the Market Access Toolkit from TELUS Health Solutions Inc. The Market Access Toolkit has been a critical resource to the pharmaceutical industry for more than 20 years. First developed ... Read More

19

Mar2020

PMPRB Has Now Published Submissions Received as Part of its Draft Guidelines Consultation

The full list of submissions can be found here under the Submissions tab at the bottom of the page. Background: On November 21, 2019, the PMPRB published its draft Guidelines and launched a public consultation as a step towards implementing the recently amended Patented Medicines Regulations. The PMPRB ... Read More

16

Mar2020

PDCI Business Operations: Business [Almost] as Usual!

Good Afternoon, At PDCI Market Access Inc. (“PDCI”) we are committed to providing high quality services and deliverables to our clients. We also recognize the important responsibility we all have to prevent the spread of the COVID-19 outbreak. Based on the information received to date, we are currently implementing the following accommodations ... Read More

10

Mar2020

PMPRB Cancellation of March 18th Policy Forum

PMPRB Cancellation of March 18th Policy Forum The Patented Medicines Prices Review Board (PMPRB) has announced the cancellation of its Policy Forum expected to be held on March 18th, 2020 amid the evolving COVID-19 situation. In order to provide stakeholders with an opportunity to convey information that may ... Read More